entertainment -WSS

entertainment

author：comprehensive 2025-09-02 08:20:58 - browse：2994

LONDON — AstraZeneca said on Monday that a new lung cancer treatment outperformed standard-of-care chemotherapy in a trial, but investors found the results less impressive than anticipated, sending company shares down in early trading.

Based on an interim analysis of a Phase 3 trial, the company said that the drug, datopotamab deruxtecan, led to improvement in progression-free survival in patients non-small cell lung cancer, a primary endpoint of the study. There was also a positive early trend on overall survival, with Susan Galbraith, AstraZeneca’s oncology leader, describing the results as “compelling evidence for the potential role” that the drug could play for patients.

But investors had been hoping for a clearer signal of benefit. Analysts noted that despite the success in progression-free survival, it was not described as a “clinically meaningful” improvement, which, as J.P. Morgan analysts wrote, “we believe the market would have liked to have seen.”

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： 23andMe had bad news about my health. I wish a person had delivered it
Next article： HHS leader on health, climate change and biopharma emissions

WSS

STAT Summit: How a Chicago ER doctor tackles gun violence

Russia's threat to pull out of Ukraine grain deal raises fears about global food security

Women's World Cup brings attention to abuse in soccer

Companies helping big Covid

STAT Summit: How a Chicago ER doctor tackles gun violence

Senate committee scrutinizes Medicare Advantage brokers

leisure time

entertainment

leisure time

23andMe had bad news about my health. I wish a person had delivered it

STAT Summit: How a Chicago ER doctor tackles gun violence

Bright Health sells Medicare Advantage business to Molina

Superbugs, antibiotic resistance get scrutiny in congress

In age of alternative facts, a scholarly course on calling out crap

CEOs share strategies for surviving biotech slump

Trump demands the U.S. pay no more for drugs than other countries … again

First Opinion Podcast: Long Covid needs a new approach

In Memoriam: Notable people who died in 2023

First Opinion Podcast: Long Covid needs a new approach

hotspot

2023 STAT Wunderkinds: get to know the winners

Kerry to visit Beijing for climate talks amid efforts to revive relations between US and China

Blinken talks high

Why health workers in Gaza are injured or die at high rates

2023 STAT Wunderkinds: get to know the winners

How are insurers handling Leqembi and related scans?

focus

entertainment

leisure time

entertainment